Characterization and estrogen stimulation of cytoplasmic progesterone receptor in the ovarian-dependent MXT-3590 mammary tumor line

C. S. Watson, D. Medina, J. H. Clark

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The purpose of this study is to characterize the cytoplasmic progesterone receptor of the ovarian-dependent MXT mouse mammary tumor line and to demonstrate that the levels of this receptor are under positive control by estrogen. MXT-3590 is a transplantable mouse mammary tumor line originally induced by urethan treatment in C57BL x DBAf F1 mice. The tumor is an ovarian-dependent well-differentiated ductal carcinoma which responds by rapid growth to estradiol benzoate and to medroxyprogesterone acetate (Depo Provera). These hormones given simultaneously result in a greater than additive growth effect. This synergism indicates that progesterone has no antagonistic effect on estrogen action as it does in many other model systems. Progesterone receptor was measured at 4° with [3H]progesterone in a brief exposure dextran-coated charcoal assay. The dissociation constant of the cytoplasmic receptor is approximately 5 nM, and the binding was specific for progesterone and its synthetic analog R5020. Specific progesterone binding appeared in both the 4S and 8S regions of 5 to 20% postlabeled sucrose density gradients. The quantity of progesterone receptor measured in MXT-3590 (28 fmol/mg tissue)falls after ovariectomy (5 fmol/mg tissue) and increases (20 fmol/mg tissue) following a s.c. injection of 2.5 μg of estradiol-17β. Thus, MXT-3590 provides evidence in an experimental mammary carcinoma for the association between estrogen action and positive progesterone receptor control. By virtue of its readily measured and well-characterized estrogen and progesterone receptors, MXT-3590 provides a promising model system in which to study growth control by estrogen and progesterone in a neoplastic tissue.

Original languageEnglish (US)
Pages (from-to)4098-4104
Number of pages7
JournalCancer Research
Volume39
Issue number10
StatePublished - 1979
Externally publishedYes

Fingerprint

Progesterone Receptors
Cytoplasmic and Nuclear Receptors
Progesterone
Estrogens
Breast Neoplasms
Medroxyprogesterone Acetate
Growth
Promegestone
Ductal Carcinoma
Charcoal
Urethane
Ovariectomy
Dextrans
Estrogen Receptors
Sucrose
Estradiol
Hormones
Injections
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Characterization and estrogen stimulation of cytoplasmic progesterone receptor in the ovarian-dependent MXT-3590 mammary tumor line. / Watson, C. S.; Medina, D.; Clark, J. H.

In: Cancer Research, Vol. 39, No. 10, 1979, p. 4098-4104.

Research output: Contribution to journalArticle

@article{60d02305c1894a23938e6976e2eead37,
title = "Characterization and estrogen stimulation of cytoplasmic progesterone receptor in the ovarian-dependent MXT-3590 mammary tumor line",
abstract = "The purpose of this study is to characterize the cytoplasmic progesterone receptor of the ovarian-dependent MXT mouse mammary tumor line and to demonstrate that the levels of this receptor are under positive control by estrogen. MXT-3590 is a transplantable mouse mammary tumor line originally induced by urethan treatment in C57BL x DBAf F1 mice. The tumor is an ovarian-dependent well-differentiated ductal carcinoma which responds by rapid growth to estradiol benzoate and to medroxyprogesterone acetate (Depo Provera). These hormones given simultaneously result in a greater than additive growth effect. This synergism indicates that progesterone has no antagonistic effect on estrogen action as it does in many other model systems. Progesterone receptor was measured at 4° with [3H]progesterone in a brief exposure dextran-coated charcoal assay. The dissociation constant of the cytoplasmic receptor is approximately 5 nM, and the binding was specific for progesterone and its synthetic analog R5020. Specific progesterone binding appeared in both the 4S and 8S regions of 5 to 20{\%} postlabeled sucrose density gradients. The quantity of progesterone receptor measured in MXT-3590 (28 fmol/mg tissue)falls after ovariectomy (5 fmol/mg tissue) and increases (20 fmol/mg tissue) following a s.c. injection of 2.5 μg of estradiol-17β. Thus, MXT-3590 provides evidence in an experimental mammary carcinoma for the association between estrogen action and positive progesterone receptor control. By virtue of its readily measured and well-characterized estrogen and progesterone receptors, MXT-3590 provides a promising model system in which to study growth control by estrogen and progesterone in a neoplastic tissue.",
author = "Watson, {C. S.} and D. Medina and Clark, {J. H.}",
year = "1979",
language = "English (US)",
volume = "39",
pages = "4098--4104",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Characterization and estrogen stimulation of cytoplasmic progesterone receptor in the ovarian-dependent MXT-3590 mammary tumor line

AU - Watson, C. S.

AU - Medina, D.

AU - Clark, J. H.

PY - 1979

Y1 - 1979

N2 - The purpose of this study is to characterize the cytoplasmic progesterone receptor of the ovarian-dependent MXT mouse mammary tumor line and to demonstrate that the levels of this receptor are under positive control by estrogen. MXT-3590 is a transplantable mouse mammary tumor line originally induced by urethan treatment in C57BL x DBAf F1 mice. The tumor is an ovarian-dependent well-differentiated ductal carcinoma which responds by rapid growth to estradiol benzoate and to medroxyprogesterone acetate (Depo Provera). These hormones given simultaneously result in a greater than additive growth effect. This synergism indicates that progesterone has no antagonistic effect on estrogen action as it does in many other model systems. Progesterone receptor was measured at 4° with [3H]progesterone in a brief exposure dextran-coated charcoal assay. The dissociation constant of the cytoplasmic receptor is approximately 5 nM, and the binding was specific for progesterone and its synthetic analog R5020. Specific progesterone binding appeared in both the 4S and 8S regions of 5 to 20% postlabeled sucrose density gradients. The quantity of progesterone receptor measured in MXT-3590 (28 fmol/mg tissue)falls after ovariectomy (5 fmol/mg tissue) and increases (20 fmol/mg tissue) following a s.c. injection of 2.5 μg of estradiol-17β. Thus, MXT-3590 provides evidence in an experimental mammary carcinoma for the association between estrogen action and positive progesterone receptor control. By virtue of its readily measured and well-characterized estrogen and progesterone receptors, MXT-3590 provides a promising model system in which to study growth control by estrogen and progesterone in a neoplastic tissue.

AB - The purpose of this study is to characterize the cytoplasmic progesterone receptor of the ovarian-dependent MXT mouse mammary tumor line and to demonstrate that the levels of this receptor are under positive control by estrogen. MXT-3590 is a transplantable mouse mammary tumor line originally induced by urethan treatment in C57BL x DBAf F1 mice. The tumor is an ovarian-dependent well-differentiated ductal carcinoma which responds by rapid growth to estradiol benzoate and to medroxyprogesterone acetate (Depo Provera). These hormones given simultaneously result in a greater than additive growth effect. This synergism indicates that progesterone has no antagonistic effect on estrogen action as it does in many other model systems. Progesterone receptor was measured at 4° with [3H]progesterone in a brief exposure dextran-coated charcoal assay. The dissociation constant of the cytoplasmic receptor is approximately 5 nM, and the binding was specific for progesterone and its synthetic analog R5020. Specific progesterone binding appeared in both the 4S and 8S regions of 5 to 20% postlabeled sucrose density gradients. The quantity of progesterone receptor measured in MXT-3590 (28 fmol/mg tissue)falls after ovariectomy (5 fmol/mg tissue) and increases (20 fmol/mg tissue) following a s.c. injection of 2.5 μg of estradiol-17β. Thus, MXT-3590 provides evidence in an experimental mammary carcinoma for the association between estrogen action and positive progesterone receptor control. By virtue of its readily measured and well-characterized estrogen and progesterone receptors, MXT-3590 provides a promising model system in which to study growth control by estrogen and progesterone in a neoplastic tissue.

UR - http://www.scopus.com/inward/record.url?scp=0018633236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018633236&partnerID=8YFLogxK

M3 - Article

C2 - 476646

AN - SCOPUS:0018633236

VL - 39

SP - 4098

EP - 4104

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 10

ER -